| pubmed-article:8829175 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8829175 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:8829175 | lifeskim:mentions | umls-concept:C0003151 | lld:lifeskim |
| pubmed-article:8829175 | lifeskim:mentions | umls-concept:C0016017 | lld:lifeskim |
| pubmed-article:8829175 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8829175 | lifeskim:mentions | umls-concept:C0660850 | lld:lifeskim |
| pubmed-article:8829175 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8829175 | pubmed:dateCreated | 1996-12-17 | lld:pubmed |
| pubmed-article:8829175 | pubmed:abstractText | Intra-ocular fibrin deposition following ocular surgery is a serious postoperative complication. The current management of severe postoperative fibrin response is usually ineffective. A quantitative model of fibrin deposition in the rabbit anterior chamber was used to assess the efficacy of Suleparoide I.N.N. (HHS-5) in preventing fibrin formation and in promoting the clearance of fibrinous membranes. Citrated human plasma was injected intracamerally after paracentesis to induce the formation of fibrin clots: 10 min or 24 h after plasma injection, solutions of HHS-5 at different concentrations were injected into the anterior chamber of rabbits. Intra-ocular HHS-5 injection 10 min after plasma injection prevented the formation of fibrinous membranes in a dose-dependent fashion in almost all treated animals. When HHS-5 was injected at 24 h after fibrin clot formation, a reduction of clot areas was observed but the membranes did not completely disappear. No evidence of ocular toxicity was detected by slit-lamp biomicroscopy, intra-ocular pressure and corneal thickness measurements. On the basis of the results obtained with the present animal model, HHS-5 appears as an effective and safe agent for the prevention of fibrinous membrane formation. The data suggest a potential use of HHS-5 for the prophylaxis of fibrin formation in human eyes undergoing extensive intraocular surgery, or in diabetic patients where a hypercoagulable state may be present. | lld:pubmed |
| pubmed-article:8829175 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8829175 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8829175 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8829175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8829175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8829175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8829175 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8829175 | pubmed:issn | 0030-3747 | lld:pubmed |
| pubmed-article:8829175 | pubmed:author | pubmed-author:NardiMM | lld:pubmed |
| pubmed-article:8829175 | pubmed:author | pubmed-author:PeriniGG | lld:pubmed |
| pubmed-article:8829175 | pubmed:author | pubmed-author:SaettoneM FMF | lld:pubmed |
| pubmed-article:8829175 | pubmed:author | pubmed-author:LepriAA | lld:pubmed |
| pubmed-article:8829175 | pubmed:author | pubmed-author:ChetoniPP | lld:pubmed |
| pubmed-article:8829175 | pubmed:author | pubmed-author:BenelliUU | lld:pubmed |
| pubmed-article:8829175 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8829175 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:8829175 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8829175 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8829175 | pubmed:pagination | 176-83 | lld:pubmed |
| pubmed-article:8829175 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:meshHeading | pubmed-meshheading:8829175-... | lld:pubmed |
| pubmed-article:8829175 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8829175 | pubmed:articleTitle | Effect of suleparoide on fibrinolysis in the anterior chamber of rabbits. | lld:pubmed |
| pubmed-article:8829175 | pubmed:affiliation | Institute of Ophthalmology, University of Pisa, Italy. | lld:pubmed |
| pubmed-article:8829175 | pubmed:publicationType | Journal Article | lld:pubmed |
